A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Inclusion Criteria: * Male or female adults between 18 and 60 years of age * Diagnosis of asthma (mild) for at least 6 months prior to Screening * Forced expiratory volume in one second (FEV1) ≥70% of predicted value at Screening * A positive skin prick test to test allergen Exclusion Criteria: * Any prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor other than IPI-145 in a previous clinical study * Acute asthma exacerbations within 6 weeks prior to Screening * Use of any medication for the treatment of asthma other than a short-acting β2 agonist (as needed) within the 4 weeks prior to Screening * Participation in another clinical study within minimum of 30 days prior to study Screening * A positive screen result for active or latent tuberculosis * A history of cardiovascular disease * The concomitant use of acid-reducing agents and cholinesterase inhibiting medication * Inadequate hepatic function defined by Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) greater than 1.5 times greater limit of normal (ULN) * Inadequate renal function defined by serum creatinine greater than 2.0 milligrams/dL